Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea B Apolo

Showing results (71-80 of 117) with videos related to

Pageof 12
Sort By:
Future Oncology (London, England)|March 21, 2025
A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)-design and rationaleNicholas Simon, Elias Chandran, Saad Atiq, et al.
Cancer|January 3, 2019
Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survivalVenkatrao Vantaku, Sri Ramya Donepudi, Danthasinghe Waduge Badrajee Piyarathna, et al.
Future Oncology (London, England)|May 16, 2026
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinomaMatthew D Galsky, Alexandra Drakaki, Arnab Basu, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2025
Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009-2023)Giovanni Maria Iannantuono, Charalampos S Floudas, Marco Filetti, et al.
Future Oncology (London, England)|May 27, 2025
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationaleElias B A Chandran, Saad Atiq, Nicholas Simon, et al.
The Lancet. Oncology|December 9, 2017
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trialManish R Patel, John Ellerton, Jeffrey R Infante, et al.
BMJ Oncology|August 1, 2024
Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysisElias B A Chandran, Giovanni Maria Iannantuono, Saad O Atiq, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2017
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib StudyAndrea B Apolo, Jeffrey R Infante, Ani Balmanoukian, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 16, 2019
Serum Metabolic Profiling Identified a Distinct Metabolic Signature in Bladder Cancer Smokers: A Key Metabolic Enzyme Associated with Patient SurvivalChandra Sekhar Amara, Chandrashekar R Ambati, Venkatrao Vantaku, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 16, 2019
<sup>18</sup>F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumabIlhan Lim, Maria Liza Lindenberg, Esther Mena, et al.
Pageof 12

Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
Future Oncology (London, England)|March 21, 2025
A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)-design and rationaleNicholas Simon, Elias Chandran, Saad Atiq, et al.
Cancer|January 3, 2019
Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survivalVenkatrao Vantaku, Sri Ramya Donepudi, Danthasinghe Waduge Badrajee Piyarathna, et al.
Future Oncology (London, England)|May 16, 2026
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinomaMatthew D Galsky, Alexandra Drakaki, Arnab Basu, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2025
Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009-2023)Giovanni Maria Iannantuono, Charalampos S Floudas, Marco Filetti, et al.
Future Oncology (London, England)|May 27, 2025
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationaleElias B A Chandran, Saad Atiq, Nicholas Simon, et al.
The Lancet. Oncology|December 9, 2017
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trialManish R Patel, John Ellerton, Jeffrey R Infante, et al.
BMJ Oncology|August 1, 2024
Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysisElias B A Chandran, Giovanni Maria Iannantuono, Saad O Atiq, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2017
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib StudyAndrea B Apolo, Jeffrey R Infante, Ani Balmanoukian, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 16, 2019
Serum Metabolic Profiling Identified a Distinct Metabolic Signature in Bladder Cancer Smokers: A Key Metabolic Enzyme Associated with Patient SurvivalChandra Sekhar Amara, Chandrashekar R Ambati, Venkatrao Vantaku, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 16, 2019
<sup>18</sup>F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumabIlhan Lim, Maria Liza Lindenberg, Esther Mena, et al.
Pageof 12